FDA declines Eli Lilly’s bowel disease drug over manufacturing issues
Pharmafile
APRIL 14, 2023
Pharma giant Eli Lilly’s Biologic Licence Application (BLA) for its bowel disease drug has been declined by the FDA over concerns about the proposed manufacturing of the drug. However, concerns weren’t expressed over the clinical data package, safety or label for the medicine.
Let's personalize your content